Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Acquisition
Alkem Laboratories' wholly-owned subsidiary, Alkem Medtech Private Limited, is set to acquire a 51-55% stake in Occlutech Holding AG. Alkem Labs has invested Rs.1,100 crore into Alkem Medtech by subscribing to its rights shares, to facilitate this strategic acquisition, which expands its presence in the medical device segment.
Jul 16 2026 14:58:06
Alkem Laboratories Ltd - 539523 - Notice Convening The Meeting Of The Equity Shareholders Of The Company Pursuant To The Order Of The Hon'Ble National Company Law Tribunal, Mumbai Bench ('NCLT') Dated June 10, 2026 ('Order')
Alkem Laboratories will convene a meeting of its equity shareholders on August 17, 2026, to seek approval for the scheme of amalgamation with its wholly-owned subsidiary, Adroit Biomed Limited. This strategic move aims to enhance efficiency, rationalize operations, and unlock value.
Jul 15 2026 15:39:21
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Alkem Laboratories board recommended a final dividend of Rs. 10 per equity share for the financial year ended March 31, 2026. This dividend is subject to shareholder approval at the upcoming 52nd Annual General Meeting, with payment scheduled for September 1, 2026, if approved.
Jul 02 2026 15:00:22
Alkem Laboratories Ltd - 539523 - Disclosure Under Regulation 30 Of SEBI LODR
Alkem Laboratories received favorable orders from the Commissioner of Income Tax (Appeals), deleting disallowances amounting to Rs. 660.77 crores. This resolution pertains to income tax assessments for AYs 2018-19 to 2022-23, reducing potential tax liabilities.
Jul 01 2026 16:57:11
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Alkem Laboratories has scheduled an in-person one-on-one meeting with Sprucegrove Investments on July 6, 2026, in Mumbai. This is part of routine investor engagement.
Jun 29 2026 11:58:21
Read More